Respiratory viral infections in lung transplantation: Recent advances in epidemiology, clinical impact, and therapeutic approaches.

Hannah Bahakel, Lara Danziger-Isakov

Abstract read

In one paragraph

Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Longitudinal Outcomes and Ribavirin Use in Lung Transplant Recipients with Respiratory Syncytial Virus or Human Metapneumovirus Infection: A Real-World Multicenter Cohort Study.Life (Basel, Switzerland) · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hannah BahakelDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Lara Danziger-IsakovDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory viruses encompass a diverse group of viruses, including influenza, respiratory syncytial virus (RSV), parainfluenza (PIV), human metapneumovirus (hMPV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and adenovirus. Lung transplant recipients are particularly vulnerable to complications from respiratory viral infections (RVIs), leading to increased morbidity and mortality. This heightened risk is a result of both anatomical and functional modifications from transplant surgery, as well as immunosuppressive therapy. Beyond the immediate morbidity associated with infection, RVIs are also recognized for their association with both acute rejection and chronic lung allograft dysfunction (CLAD)/bronchiolitis obliterans syndrome (BOS). This article provides updated insights into epidemiology, clinical outcomes, prevention strategies, and treatment options for RVIs in lung transplant recipients.

Indexed as

InfluenzaLung transplantationRespiratory syncytial virusRespiratory viral infectionsVaccination

Identifiers

PMID40893635

DOI10.1016/j.jhlto.2025.100362

PMCPMC12396496

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.